IP Library Granted Patent US 9,090,574
Granted Patent B2
US 9,090,574 · App. 13/867,797 · Granted Jul 28, 2015

Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the C-ring

Inventors: Eric Anderson (Southlake, TX); Xin Jiang (Dallas, TX); Xiaofeng Liu (Dallas, TX); Melean Visnick (Irving, TX)
Assignee: Reata Pharmaceuticals, Inc.
C07D261/20C07C69/757C07D207/27C07D413/08C07J63/008
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,090,574
App. No.
13/867,797
Granted
Jul 28, 2015
Kind
B2
Abstract

This invention provides, but is not limited to, novel oleanolic acid derivatives having the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds, methods and intermediates useful for making the compounds, and methods of using the compounds and compositions.

Claims (51)

1. A compound of the formula:

wherein:

Y is cyano or —C(O)R a , wherein

R a is:

hydrogen, hydroxy, halo, amino, hydroxyamino, azido or mercapto; or

alkyl (C≦12) , alkenyl (C≦12) , alkynyl (C≦12) , aryl (C≦12) , aralkyl (C≦12) , heteroaryl (C≦12) , heteroaralkyl (C≦12) , alkoxy (C≦12) , alkenyloxy (C≦12) , alkynyloxy (C≦12) , aryloxy (C≦12) , aralkoxy (C≦12) , heteroaryloxy (C≦12) , heteroaralkoxy (C≦12) , acyloxy (C≦12) , alkylamino (C≦12) , dialkylamino (C≦12) , alkoxyamino (C≦12) , alkenylamino (C≦12) , alkynylamino (C≦12) , arylamino (C≦12) , aralkylamino (C≦12) , heteroarylamino (C≦12) , heteroaralkylamino (C≦12) , alkylsulfonylamino (C≦12) , amido (C≦12) , alkylthio (C≦12) , alkenylthio (C≦12) , alkynylthio (C≦12) , arylthio (C≦12) , aralkylthio (C≦12) , heteroarylthio (C≦12) , heteroaralkylthio (C≦12) , acylthio (C≦12) , alkylammonium (C≦12) , alkylsulfonium (C≦12) , alkylsilyl (C≦12) , or a substituted version of any of these groups;

X is OR b , NR b R c , or SR b , wherein R b and R c are each independently:

hydrogen;

alkyl (C≦8) , aryl (C≦8) , aralkyl (C≦8) , acyl (C≦8) , or a substituted version of any of these groups; or

provided that R b is absent when the atom to which it is bound is part of a double bond, further provided that when R b is absent the atom to which it is bound is part of a double bond; and

R 1 is:

hydrogen, cyano, hydroxy, halo or amino; or

alkyl (C≦8) , alkenyl (C≦8) , alkynyl (C≦8) , aryl (C≦8) , aralkyl (C≦8) , heteroaryl (C≦8) , heteroaralkyl (C≦8) , acyl (C≦8) , alkoxy (C≦8) , aryloxy (C≦8) , acyloxy (C≦8) , alkylamino (C≦8) , arylamino (C≦8) , amido (C≦8) , or a substituted version of any of these groups;

or a salt or tautomer thereof.

2. A compound of the formula:

wherein:

Y is cyano or —C(O)R a , wherein

R a is:

hydrogen, hydroxy, halo, amino, hydroxyamino, azido or mercapto; or

alkyl (C≦12) , alkenyl (C≦12) , alkynyl (C≦12) , aryl (C≦12) , aralkyl (C≦12) , heteroaryl (C≦12) , heteroaralkyl (C≦12) , alkoxy (C≦12) , alkenyloxy (C≦12) , alkynyloxy (C≦12) , aryloxy (C≦12) , aralkoxy (C≦12) , heteroaryloxy (C≦12) , heteroaralkoxy (C≦12) , acyloxy (C≦12) , alkylamino (C≦12) , dialkylamino (C≦12) , alkoxyamino (C≦12) , alkenylamino (C≦12) , alkynylamino (C≦12) , arylamino (C≦12) , aralkylamino (C≦12) , heteroarylamino (C≦12) , heteroaralkylamino (C≦12) , alkylsulfonylamino (C≦12) , amido (C≦12) , alkylthio (C≦12) , alkenylthio (C≦12) , alkynylthio (C≦12) , arylthio (C≦12) , aralkylthio (C≦12) , heteroarylthio (C≦12) , heteroaralkylthio (C≦12) , acylthio (C≦12) , alkylammonium (C≦12) , alkylsulfonium (C≦12) , alkylsilyl (C≦12) , or a substituted version of any of these groups;

X is OR b , NR b R c , or SR b , wherein R b and R c are each independently:

hydrogen;

alkyl (C≦8) , aryl (C≦8) , aralkyl (C≦8) , acyl (C≦8) , or a substituted version of any of these groups; or

provided that R b is absent when the atom to which it is bound is part of a double bond, further provided that when R b is absent the atom to which it is bound is part of a double bond; and

R 1 is:

hydrogen, cyano, hydroxy, halo or amino; or

alkyl (C≦8) , alkenyl (C≦8) , alkynyl (C≦8) , aryl (C≦8) , aralkyl (C≦8) , heteroaryl (C≦8) , heteroaralkyl (C≦8) , acyl (C≦8) , alkoxy (C≦8) , aryloxy (C≦8) , acyloxy (C≦8) , alkylamino (C≦8) , arylamino (C≦8) , amido (C≦8) , or a substituted version of any of these groups;

R′ is hydroxy, alkoxy (C≦12) , substituted alkoxy (C≦12) , aryloxy (C≦12) , substituted aryloxy (C≦12) , aralkoxy (C≦12) , substituted aralkoxy (C≦12) , acyloxy (C≦12) , or substituted acyloxy (C≦12) ;

or a salt or tautomer thereof.

3. The compound of claim 1 , wherein Y is cyano.

4. The compound of claim 1 , wherein Y is —C(O)R a .

5. The compound of claim 1 , wherein X is OR b .

6. The compound of claim 5 , wherein R b is absent.

7. The compound of claim 5 , wherein R b is hydrogen.

8. The compound of claim 4 , wherein R a is hydroxy.

9. The compound of claim 4 , wherein R a is alkoxy (C≦6) , aryloxy (C≦8) , aralkyloxy (C≦8) , or a substituted version of any of these groups.

10. The compound of claim 9 , wherein R a is alkoxy (C1-2) or substituted alkoxy (C1-2) .

11. The compound of claim 10 , wherein R a is methoxy.

12. The compound of claim 4 , wherein R a is amino.

13. The compound of claim 4 , wherein R a is alkylamino (C1-6) , alkoxyamino (C1-6) , arylamino (C1-8) , aralkylamino (C1-8) , dialkylamino (C2-8) , or a substituted version of any of these groups.

14. The compound of claim 13 , wherein R a is substituted alkylamino (C1-3) .

15. The compound of claim 14 , wherein R a is 2,2,2-trifluoroethylamino.

16. The compound of claim 1 , wherein R 1 is —H.

17. The compound of claim 2 , wherein R′ is acetyloxy.

18. The compound of claim 2 , wherein R′ is hydroxy.

19. The compound of claim 1 , further defined as:

substantially free from other optical isomers thereof.

20. The compound of claim 1 , further defined as:

Or a salt or tautomer thereof.

21. The compound of claim 2 , further defined as:

substantially free from other optical isomers thereof.

Assignments (7)
RELEASE OF SECURITY INTEREST Recorded Apr 9, 2025
From: BIOPHARMA CREDIT PLC
To: REATA PHARMACEUTICALS HOLDINGS, LLC; REATA PHARMACEUTICALS GLOBAL, INC.; REATA PHARMACEUTICALS, INC.
Reel/Frame 070793/0228 →
RELEASE OF SECURITY INTEREST Recorded Apr 9, 2025
From: BIOPHARMA CREDIT PLC
To: REATA PHARMACEUTICALS HOLDINGS, LLC; REATA PHARMACEUTICALS GLOBAL, INC.; REATA PHARMACEUTICALS, INC.
Reel/Frame 070793/0130 →
AMENDED AND RESTATED PATENT SECURITY AGREEMENT Recorded Jul 12, 2023
From: REATA PHARMACEUTICALS HOLDINGS, LLC; REATA PHARMACEUTICALS GLOBAL, INC.; REATA PHARMACEUTICALS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 064264/0557 →
PATENT SECURITY AGREEMENT Recorded May 18, 2023
From: REATA PHARMACEUTICALS HOLDINGS, LLC; REATA PHARMACEUTICALS GLOBAL, INC.; REATA PHARMACEUTICALS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 063697/0461 →
RELEASE OF SECURITY INTEREST Recorded Jun 24, 2020
From: OXFORD FINANCE LLC, AS COLLATERAL AGENT
To: REATA PHARMACEUTICALS, INC.
Reel/Frame 053034/0018 →
SECURITY INTEREST Recorded Jun 14, 2018
From: REATA PHARMACEUTICALS, INC.
To: OXFORD FINANCE LLC, AS COLLATERAL AGENT
Reel/Frame 046357/0605 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 13, 2015
From: ANDERSON, ERIC; JIANG, XIN; LIU, XIAOFENG; VISNICK, MELEAN
To: REATA PHARMACEUTICALS, INC.
Reel/Frame 036783/0771 →
Continuity (6)
Continuation 13348500 · Jan 11, 2012
Continuation 13033452 · Feb 23, 2011
Continuation 12426737 · Apr 20, 2009
Provisional Application 61111333 · Nov 4, 2008
Provisional Application 61046332 · Apr 18, 2008
Related Publication 20140179928A1 · Jun 26, 2014